Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Full blood count, Hypersensitivity, Inappropriate schedule of product administration, Laboratory test, Loss of personal independence in daily activities
Clinical narrative: Allergic reaction; rash, raised red / Raised red rash; Body aches; fatigue/ extreme fatigue; malaise; decrease function; weight gain of 15 in 5 weeks; Fever; joint pain; Generalized urticaria; Generalized erythema; Generalized pruritus with skin rash; Generalized prickle sensation; Localized injection site urticaria; Red and itchy eyes; Red and itchy eyes; Diarrhea; Nausea; Vomiting; skin aches; inappropriate schedule of vaccine administered; rash / Generalized pruritus with skin rash; This is a spontaneous report from a contactable nurse (patient herself). A 55-years-old non pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: EW0151, Expiration date: Unknown), via intramuscular route of administration in Right Deltoid on 01Jun2021 at 15:00 as dose 2, single (at the age of 55-years old) for COVID-19 immunization. The patient was not pregnant at the time of vaccination. The patient was not diagnosed with COVID-19 prior vaccination. The patient was not tested for COVID-19 post vaccination. The patient's medical history and family history included known allergies with sulfa, aspartame from 1984, gastric reflux, heart disease and diabetes mellitus from an unknown date and unknown if ongoing. The patient's concomitant medications included omeprazole (40 mg every day) taken for an unspecified indication, diazepam (VALIUM) taken (5 mg as PRN) for insomnia, nature's bounty hair, skin and nails vitamin (Vitamin D 50000 IU every week), start and stop date were not reported. The patient previously took past drugs aspartame for drug hypersensitivity, BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: EW0151, Expiration date: Unknown), via intramuscular route of administration in Right Deltoid on 21May2021 at 15:00 as dose 1, single for COVID-19 immunization and experienced injection site pain. On 01Jun2021 at 04:00, the patient experienced rash/generalized pruritus with skin rash. On 01Jun2021, at 15:00, the patient experienced inappropriate schedule for vaccine administered. On 02Jun2021 at 02:00, the patient experienced a rash, raised red/raised red rash, body aches, skin aches, fatigue and malaise. On 02Jun2021, the patient experienced decreased function, weight gain, fever, joint pain, generalized urticaria, generalized erythema, generalized pruritis with skin rash, generalized prickle sensation, localized injection site urticaria, red and itchy eyes, diarrhea, nausea and vomiting. On 12Jun2021 at 02:00, the patient experienced allergic reaction. It was reported that the event extreme fatigue was not recovered, body aches, raised allergic reaction type rash and skin pain lasted approximately 3 days severe enough to decrease function, weight gain of 15 in 5 weeks. Rash and most of her symptoms subsided in 3 days. The patient was not visited or seen the emergency department. The patient was not admitted to an intensive care unit. The patient had a multiorgan involvement. The patient underwent lab tests and procedures which included full blood count as normal, laboratory test as normal on 19Aug2021, weight gain of 15 units in 5 weeks and CBC CMP was normal on 19Aug2021. The outcome of the events Raised red rash, Fever, Malaise, body aches, skin aches, fatigue, joint pain, decreased function weight gain 15 in 5 weeks was not recovered. The outcome of the events generalized urticaria, erythema, skin rash, prickle sensation, localized injection site urticaria, red and itchy eyes, gastrointestinal, diarrhea, nausea and vomiting was recovered on an unspecified date Jun2021.   Follow-up attempts are completed. No further information is expected.